Psoriatic Immune Response to Tildrakizumab
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• 18 years of age or older
• Patients with moderate-severe psoriasis or \> 5% body surface area affected.
Locations
United States
California
University of California, San Francisco
RECRUITING
San Francisco
Contact Information
Primary
Raymond Cho, MD, PhD
rashes@ucsf.edu
415-575-0524
Time Frame
Start Date: 2022-09-01
Estimated Completion Date: 2028-09-01
Participants
Target number of participants: 10
Treatments
Experimental: Tildrakizumab treatment
Biological/vaccine: tildrakizumab
Related Therapeutic Areas
Sponsors
Leads: University of California, San Francisco
Collaborators: Sun Pharmaceutical Industries Limited